Chanda Sanjay — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Chanda Sanjay is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $9K.
Profile
Sanjay Chanda is the Chief Development Officer of AN2 Therapeutics, Inc., a biopharmaceutical company focused on boron-based small molecule therapeutics. Appointed to lead development strategy and execution for the company’s pipeline, Chanda serves as a key member of AN2 Therapeutics’ executive leadership. AN2 Therapeutics concentrates on treatments for infectious diseases and oncology using its boron chemistry platform.
Role
Insider
Notability
40/100
Board memberships
AN2 Therapeutics, Inc.
Awards & honors
Led development planning for boron-based small molecules
Sanjay Chanda is the Chief Development Officer of AN2 Therapeutics, Inc., a biopharmaceutical company focused on boron-based small molecule therapeutics. Appointed to lead development strategy and execution for the company’s pipeline, Chanda serves as a key member of AN2 Therapeutics’ executive leadership. AN2 Therapeutics concentrates on treatments for infectious diseases and …
Has Chanda Sanjay been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($9K) across all tracked filings.
Where can I see all of Chanda Sanjay's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
